CNTX_OUT_1 [2025-04-02 12:26:36 -0400] 2894 Bytes | 789 tokens | Cum: 789 tkns (9.86% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 12:26:36 PM on Wed Apr 02, 2025 -0400, and I'm firing up the spotlight on Context Therapeutics (CNTX), moving from 0.5511 to 0.6374. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: Context Therapeutics (CNTX)
IPO: 2021-10-20 (3 Years Ago)
Market Cap: $49,435,981
Shares Outstanding: 89,700,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Here's the first list of news for Context Therapeutics:

C1 - Apr-01-25 07:30AM - Context Therapeutics to Participate in Upcoming Investor Conferences
C2 - Mar-26-25 04:02PM - Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
C3 - Mar-20-25 04:22PM - Context Therapeutics Reports Full Year 2024 Operating and Financial Results
C4 - Feb-24-25 05:05PM - Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
C5 - Feb-19-25 07:30AM - Context Therapeutics to Participate in Upcoming Investor Conferences
C6 - Jan-15-25 11:29AM - Context doses first subject in Phase I cancer trial of CTIM-76
C7 - Jan-14-25 04:58PM - Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
C8 - Jan-13-25 07:30AM - Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Prior AI Reports for CNTX:
1. 2025-03-25 – Score: 56 – Target: 1.4500 – Highs: 0.9899 / 0.8799 / 0.81
context-therapeutics-shows-promise-despite-quarterly-performance-dip

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Context Therapeutics (CNTX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

CNTX_OUT_3 [2025-04-02 12:26:39 -0400] 1106 Bytes | 313 tokens | Cum: 1104 tkns (13.80% of 8k)
==========================================================================

Showing C3 (chunk 1 of 7): C3:
**Context Therapeutics Reports Full Year 2024 Operating and Financial Results**
Date: Mar-20-25 04:22PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/20/3046728/0/en/Context-Therapeutics-Reports-Full-Year-2024-Operating-and-Financial-Results.html

March 20, 2025 16:22 ET| Source:Context Therapeutics Inc.Context Therapeutics Inc.

Cash and cash equivalents of $94.4 million as of December 31, 2024

Company expects its cash and cash equivalents will continue to fund operations into 2027

PHILADELPHIA, March 20, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2024, and reported on recent and upcoming business highlights.

Martin

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CNTX_OUT_5 [2025-04-02 12:26:40 -0400] 1000 Bytes | 263 tokens | Cum: 1434 tkns (17.93% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T11:45:19Z - Context Therapeutics to Participate in Upcoming Investor Conferences | Taiwan News | Apr. 1, 2025 19...
A2 - 2025-04-01T11:40:29Z - Context Therapeutics to Participate in Upcoming Investor Conferences...
A3 - 2025-03-26T20:03:09Z - Context Therapeutics Announces Poster Presentation at the American Association for Cancer ......
A4 - 2025-03-26T20:14:52Z - Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (...
A5 - 2025-03-26T20:14:54Z - Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CNTX_OUT_7 [2025-04-02 12:26:45 -0400] 1098 Bytes | 330 tokens | Cum: 1766 tkns (22.07% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Context Therapeutics to Participate in Upcoming Investor Conferences | Taiwan News | Apr. 1, 2025 19:30**Date: 2025-04-01Source: {'uri': 'taiwannews.com.tw', 'dataType': 'news', 'title': 'Taiwan News'}URL: https://taiwannews.com.tw/en/news/6074562PHILADELPHIA, April 01, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its participation in several upcoming investor conferences:

Upcoming Investor Conferences

Stifel Virtual Targeted Oncology Forum, April 8-9, 2025

Presentation: Tuesday, April 8 at 10:00 AM ET

1x1 Meetings on April 8 - 9th Jones Healthcare and Technology Innovation Conference in Las Vegas, April 8-9, 2025

1x1 Meetings on April 9th 24th Annual Needham Virtual Healthcare Conference, April 7-10, 20

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CNTX_OUT_9 [2025-04-02 12:26:46 -0400] 862 Bytes | 288 tokens | Cum: 2168 tkns (27.10% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-14T21:58:00Z - Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
B2 - 2024-12-26T16:26:00Z - Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
B3 - 2024-12-20T20:45:00Z - Top 10 Small-Cap Stocks to Watch in 2025
B4 - 2024-06-12T13:40:09Z - Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?
B5 - 2024-05-20T16:00:10Z - Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice
B6 - 2024-05-14T16:00:08Z - Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CNTX_OUT_11 [2025-04-02 12:26:49 -0400] 812 Bytes | 237 tokens | Cum: 2407 tkns (30.09% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/14/3009673/0/en/Context-Therapeutics-Announces-First-Patient-Dosed-in-the-Phase-1-Clinical-Trial-of-CTIM-76.htmlContext Therapeutics Inc. announced the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody, for CLDN6-positive gynecologic and testicular cancers. The company expects to share initial data in the first half of 2026.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CNTX_OUT_13 [2025-04-02 12:26:49 -0400] 1117 Bytes | 263 tokens | Cum: 2754 tkns (34.42% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-20 10-K Item 7. Management's Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other finan...

S2 - 2025-03-20 10-K Item 7. Management's Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other finan...

S7 - 2025-01-14 8-K Item 7.01. Regulation FD Disclosure.

On January 14, 2025, Context Therapeutics Inc. (the "Company") issued a press release announcing that the first patient has been dosed in the Companys Phase 1 clinical trial evaluating CTIM-76. A copy of the press release is attached as Exhi...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CNTX_OUT_15 [2025-04-02 12:26:50 -0400] 1098 Bytes | 226 tokens | Cum: 2982 tkns (37.28% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this Form 10-K. Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business, contains forward-looking statements that involve risks and uncertainties. You should review the section titled Risk Factors in this Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described below. Please also see the section entitled Note Regarding Forward-Looking Statements.

Overview

We are a clinical-stage biopharmaceutical company advanc

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CNTX_OUT_17 [2025-04-02 12:27:04 -0400] 4950 Bytes | 1428 tokens | Cum: 4412 tkns (55.15% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+----------------------+
| Volume: 78,122 | Perf Month: -24.46% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 160.37K | Perf Quarter: -40.18% | Short Float: 4.54% | ROE: -49.89% |
+---------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 1.11 | Index: - | Short Ratio: 14.81 | ROI: -28.02% |
+---------------------+-----------------------+------------------------+----------------------+
| RSI (14): 40.71 | Market Cap: 56.89M | Short Interest: 2.37M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.09 | Shs Outstand: 89.70M | Beta: 2.18 | EPS Surprise: 67.39% |
+---------------------+-----------------------+------------------------+----------------------+
| SMA20: -14.09% | Shs Float: 52.33M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA50: -21.64% | Inst Own: 47.51% | Sales past 5Y: 0.00% | Earnings: Mar 20 AMC |
+---------------------+-----------------------+------------------------+----------------------+
| SMA200: -61.19% | Insider Own: 41.67% | Employees: 12 | |
+---------------------+-----------------------+------------------------+----------------------+
| Perf Week: -19.83% | Insider Trans: 0.00% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Context Therapeutics Inc. (CNTX) by Minai-Azary Jennifer Lynn (Chief Financial Officer) on 2025-02-13
- Stock Option (right to buy): 371800 shares at $0 (D)

Inside Trans: Context Therapeutics Inc. (CNTX) by Levit Alex C. (Chief Legal Officer, Corp. Sec) on 2025-02-13
- Stock Option (right to buy): 349900 shares at $0 (D)

Inside Trans: Context Therapeutics Inc. (CNTX) by Dansky Ullmann Claudio (Chief Medical Officer) on 2025-02-13
- Stock Option (right to buy): 174960 shares at $0 (D)

Inside Trans: Context Therapeutics Inc. (CNTX) by Lehr Martin A. (Chief Executive Officer) on 2025-02-13
- Stock Option (right to buy): 802700 shares at $0 (D)

Inside Trans: Context Therapeutics Inc. (CNTX) by Pasternak Andy (Unknown Title) on 2025-01-13
- Stock Option (right to buy): 20685 shares at $0 (D)

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -26725104.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.64
Average Volume: 84536.48
30-Day High: 0.865
30-Day Low: 0.5511

[Detailed Financials: TTM 2024]
- Total Assets: $98,126,759.0
- Total Liabilities: $2,860,497.0
- Total Equity: $95,266,262.0
- Current Assets: $97,895,984.0
- Current Liabilities: $2,748,433.0

[Income Statement: TTM 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.46

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $79,979,997.0

[Detailed Financials: FY 2024]
- Total Assets: $98,126,759.0
- Total Liabilities: $2,860,497.0
- Total Equity: $95,266,262.0
- Current Assets: $97,895,984.0
- Current Liabilities: $2,748,433.0

[Income Statement: FY 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.46

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $79,979,997.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

CNTX_OUT_19 [2025-04-02 12:27:07 -0400] 676 Bytes | 167 tokens | Cum: 4827 tkns (60.34% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

CNTX_IN_21 [2025-04-02 12:27:07 -0400] 126 Bytes | 29 tokens | Cum: 4908 tkns (61.35% of 8k)
==========================================================================

====================================
[2025-04-02 12:27:07] # Analysis Completed
Elapsed Time: 31.46 seconds